SINOPHARM (01099) has released the interim results of its subsidiary, China National Accord Medicines Corporation Ltd., for the six months ended June 30, 2026.
The subsidiary recorded total operating revenue of 36.266 billion yuan, a decrease of 1.44% compared to the same period last year. Net profit attributable to shareholders of the listed company stood at 606 million yuan, marking an 8.97% decline year-on-year.
Basic earnings per share for the period were 0.99 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.